Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer,
with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. Currently …

Oncolytic virotherapy is an emerging treatment modality that uses replication-competent
viruses to destroy cancers. Recent advances include preclinical proof of feasibility for a …

Viruses are obligate intracellular parasites, and their replication requires host cell functions.
Although the size, composition, complexity, and functions encoded by their genomes are …

Glioblastoma (GBM) is the most common type of primary brain tumor in adults. Despite
recent advances in cancer therapy, including the breakthrough of immunotherapy, the …

Oncolytic virus (OV) therapy is an emerging anti-cancer approach that utilizes viruses to
preferentially infect and kill cancer cells, while not harming healthy cells. Vesicular stomatitis …

Viruses are obligate intracellular parasites; they heavily depend on the host cell machinery
to effectively replicate and produce new progeny virus particles. Following viral infection …

Purpose: Next-generation sequencing studies and CRISPR-Cas9 screens have established
mutations in the IFNγ-JAK-STAT pathway as an immune checkpoint inhibitor (ICI) resistance …

Small-molecule inhibitor of apoptosis (IAP) antagonists, called Smac mimetic compounds
(SMCs), sensitize tumours to TNF-α-induced killing while simultaneously blocking TNF-α …

The protozoan parasite Leishmania alters the activity of its host cell, the macrophage.
However, little is known about the effect of Leishmania infection on host protein synthesis …

Active-site mTOR inhibitors (asTORi) hold great promise for targeting dysregulated mTOR
signaling in cancer. Because of the multifaceted nature of mTORC1 signaling, identification …